Conditions: Sleep Initiation and Maintenance Disorders Mental Disorders Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 184
Healthy volunteers: no

Brief summary:
This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).

Detailed description:

Arms:
arm 1: Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.

Interventions: intervention 1: esmirtazapine
Intervention descriptions: intervention 1: None

Protocol document: